Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Z-1018 vs Shingrix in Healthy Adults 50-69 Years
NCT05245838Phase 1Completed
- Sponsor
- Dynavax Technologies
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- Prophylactic Vaccines, Antisense DNA, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of glycoprotein E + CpG 1018 in herpes zoster (HZ) (5 arms), sponsored by Dynavax Technologies. Primary endpoints: Frequency of solicited local and systemic post-injection reactions (PIRs) 7 days after administration of study vaccine (Dose 1), Frequency of solicited local and systemic post-injection reactions (PIRs) 7 days after administration of study vaccine (Dose 2) and 2 more. Started Jan 2022; status: completed.
02
Drugs
glycoprotein E + CpG 1018
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT05245838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05245838.